|
Amulet’s LAAO Edge | Proteinuria Predicts SCA
March 20, 2025
|
|
|
|
|
Together with
|
|
|
|
“In many settings, we have physicians and non-physicians performing the same job. This begs the question of whether the physicians are overtrained or the non-physicians are undertrained for that job.”
|
|
Dr. David Chan, MD
|
|
|
|
Although there’s still ongoing debate on who should receive LAAO devices, new five year results from the Amulet IDE trial confirm that both Abbott’s Amulet occluder and Boston Scientific’s Watchman 2.5 are safe and effective in the long run.
- LAAO (left atrial appendage occlusion) devices help prevent stroke in patients with AFib by sealing off the left atrial appendage where blood clots can form.
- Devices like the Amulet and Watchman provide an alternative to anticoagulants for AFib stroke prevention in patients who cannot take blood thinners.
Amulet IDE set Abbott’s contender against Boston Scientific’s Watchman 2.5 (its three generation old model), randomizing 1.9k patients to receive either the Amulet or Watchman and found that both devices had similar five year clinical outcomes, although Amulet held an edge in a couple key categories.
- The Amulet and Watchman devices were nearly tied for the study’s composite rate of ischemic stroke or systemic embolism after five years (7.4% vs. 7.1%).
- Both devices also had a similar rate of major bleeding (20.1% for Amulet vs. 20.0% for Watchman), CV death (14.3% vs 15.4%), and all-cause death (28.7% vs 31.1%).
- However, Amulet beat the Watchman when it came to oral anticoagulation use, since more Amulet patients remained OAC free after five years (94% vs. 90.9%).
The results of Amulet IDE also suggest that patients who experienced stroke during the study faced less severe strokes with the Amulet (nondisabling = 38, disabling = 11, fatal = 11) than with the Watchman (nondisabling = 19, disabling = 22, fatal = 17).
While the jury is still out on which patients need LAAO, the study only included adults at a high risk of stroke or systemic embolism with a CHADS2 score ≥2 or CHA2DS2-VASc score ≥3.
The Takeaway
The five year results from the Amulet IDE trial confirm that whether it’s an Amulet or a Watchman, both LAAO devices are likely to do their jobs well, but we’ll probably need more studies to confirm whether Amulet truly has a stroke severity and OAC advantage.
|
|
|
Explore Vitrea Advanced Visualization
Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow
|
|
The New Way to CMR
Cardiac MRI is infamous for its complexity and backlogs, but it doesn’t need to be that way. See how Vista.ai’s Vista Cardiac solution automates and simplifies image acquisition so all technologists can perform a CMR scan with quality, consistency, and efficiency.
|
|
Monebo’s Customers Lead the Way
Monebo’s customers span across the globe, and range from local cardiac monitoring companies to major ECG OEMs. See what they all have in common, and how the Monebo monitoring advantage might help your business.
|
|
- Proteinuria Predicts SCA? We already know that proteinuria is a risk factor for cardiovascular events, but it could also be used to predict sudden cardiac arrest (SCA) in younger adults. A recent AHA study found that individuals aged 20-39 with proteinuria had a higher incidence of SCA (0.19) than those without proteinuria (0.09). When adjusting for confounding variables, participants with stages +3–4 of proteinuria showed a significant increase in SCA risk (aHR: 2.94).
- GE’s AltiX AI.i Update: GE HealthCare launched the AltiX AI.i edition of its Mac-Lab, CardioLab, and ComboLab workflow software. The AltiX AI.i editions are designed to improve the user experience by elevating workflows in the cath lab and supporting complex electrophysiology procedures. These latest editions include an integrated diastolic pressure ratio algorithm, improved signal quality, and real-time AI assessments for AFib risk.
- Rona’s HTG Drug: RNA-targeted drug developer Rona Therapeutics announced that the FDA granted Investigational New Drug clearance for RN0361, its APOC3 targeting siRNA therapeutic that treats hypertriglyceridemia, mixed dyslipidemia, and familial chylomicronemia syndrome. Rona plans to advance RN0361 to a Phase 2 trial in HTG patients thanks to its strong safety profile and sustained triglyceride reduction in a recent Phase 1 clinical trial. The upcoming Phase 2 RCT will have a nine-month follow-up to explore the drug’s long term safety and efficacy.
- Smart Meter & FibriCheck’s AFib App: Smart Meter and FibriCheck launched their AFib detection app in the U.S., turning users’ smartphones into diagnostic tools. The FDA-cleared FibriCheck mobile app uses custom algorithms and the smartphone’s camera to monitor irregular heart rhythms for AFib while integrating with Smart Meter’s RPM platform to give healthcare professionals real-time heart rhythm data. Users who need rhythm monitoring just place a finger over the smartphone’s camera lens to perform a non-invasive heart rhythm check anytime.
- CS Transfer Risks & Benefits: A recent AHA study suggests transferring patients with cardiogenic shock to larger hub hospitals could lead to better outcomes versus more local care centers. Researchers analyzed over 300k CS cases in the Nationwide Readmissions Database and found that transferred patients (9.8% of cases) faced lower in-hospital mortality compared to non-transferred patients (39.1% vs. 47.1%). However, transferred patients had higher complication rates and more frequent all-cause (+21%) and cardiac HF (+14%).
- HeartLung to Launch AutoChamber at ACC: HeartLung Technologies is planning to use ACC 2025 to launch its AutoChamber software for analyzing chest CT scans to detect cardiomegaly and enlarged cardiac chambers that are often missed on routine CT. The application estimates cardiac volume, cardiac chamber volumes, and left ventricular wall mass, and results can be added to coronary artery calcium and CCTA scans. HeartLung and AutoChamber will also be competing in ACC’s Early-Stage Innovation Pitch Challenge.
- Calcium & Cardiomyocytes: Although cardiomyocytes lost during ischemic cardiac injury can’t be replaced, new research suggests calcium regulation could help with new cell proliferation. As part of a Nature study, researchers screened proteins involved in CM calcium cycling in human embryonic stem cell-derived cardiac organoids and revealed that only the inhibition of L-Type Calcium Channel induces the cardiomyocyte cell cycle. Researchers then combined RRAD/CDK4/CCND gene expression with LTCC inhibition and found it improved cardiac function and reduced scar size post-MI.
- STEMI Guidelines Unmet: Data analysis from the AHA’s GWTG-CAD registry uncovered significant institutional-level variability in meeting the first medical contact to device time guidelines for STEMI patients. Approximately 60% of sites were able to achieve a FMC-to-device time of less than 90 minutes for primary presentations, but only 11% achieved the target in at least three quarters of admitted STEMI patients. The analysis also suggested that failure to meet the guidelines leads to worse outcomes.
- The Nickel Risk in PFO Closure: Nickel-sensitive patients may face higher risks with PFO closure. In a randomized study of 96 patients, those with nickel hypersensitivity (29%) were 10.5 times more likely to develop “device syndrome”—a mix of chest pain, palpitations, migraines, dyspnea, and rash (71.4% vs. 20.6%). There was no impact on stroke or arrhythmias, and both the Amplatzer and Gore Cardioform devices performed similarly.
- AccurKardia’s New Senior Advisor: ECG analytics company AccurKardia bolstered its growing leadership team with the addition of Sanjiv Arora as its newest Senior Advisor. Arora joins AccurKardia with over 35 years of medtech leadership at companies like Solventum, Medtronic, and Edwards Lifesciences. AccurKardia will apply Sanjiv’s expertise in corporate strategy to expand its ECG software’s reach while growing its advisory panel that already includes digital health expert Ken Nelson and finance leader Francisco Martorell.
- Integrating Evidence for Digital Tech: The power trio of DiMe, Peterson Health Technology Institute, and advisory firm ZS released awesome public resources to help health tech developers meet the evidence needs of different stakeholders on the path to commercialization (regulators, investors, payors, etc.). The resources are nicely broken down for different startup stages, and include an IEP Toolkit (comprehensive roadmap for building evidence plans), a Stakeholder Map (self-explanatory), and a High-Quality Evidence Checklist (for ensuring evidence aligns with decision makers).
|
|
Merge Still Best in KLAS
Merge Cardio and Merge Hemo continued their KLAS hot streak, ranking Best in KLAS 2025 for Cardiology and Hemodynamics for the 10th and 13th years. Discover the user enhancements and software improvements that led to Merge Cardio and Merge Hemo’s latest wins.
|
|
Experience the Future of Learning: Medtronic Academy 2.0 is Here!
Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
|
|
AI Analysis of ATTR-CM
ATTR-CM is a progressive and fatal cardiomyopathy with a rising number of diagnoses and a highly variable clinical course. See how Us2.ai’s fully automated machine learning algorithm analyzes echocardiographic DICOM images without human interaction to improve tracking ATTR-CM progression and treatment responses.
|
|
- Automate Your Echo Reporting: It’s a good feeling when your echo report is already 83% complete before you even sit down to work on it. See how Centricity Cardio Enterprise’s echo automation features make this “good feeling” an everyday occurrence in this quick GE HealthCare demo video.
- Offer Hope Not Just Inotrope to Your Patients with Advanced Heart Failure: Left ventricular assist devices (LVADs) have received Level 1A Recommendation from the AHA/ACC/HFSA guidelines.
- New Horizons in Structural Heart: TAVR and TMVR rates are rising rapidly, placing more pressure on interventional planning. Tune into this Circle CVI and Radcliffe Cardiology breakout detailing how to leverage modern CT workflows to produce efficient and accurate pre-procedural plans.
- Cardiology AI: From Research to Clinical Practice: Explore how AI algorithms are reshaping cardiology with insights from Tempus’ recent webinar, featuring Dr. David Ouyang of UCLA and Cedars-Sinai, alongside Tempus’ Dr. John Pfeifer and Dr. Brandon Fornwalt. This expert panel dives into how AI can bridge diagnostic gaps, enhance patient outcomes, and streamline workflows for conditions like AFib and pulmonary hypertension. Read the full recap to glimpse the future of AI-driven cardiology.
- An All-in-One Coronary Care Solution: See how HeartFlow ONE is transforming precision heart care as the first all-in-one CCTA pathway, combining FFRCT, stenosis, and plaque analysis in a single workflow.
- Innovating AFib Care: The first manifestation of AFib is often stroke, but many hospitals aren’t set up to coordinate these patients’ post-stroke care. See how UCSD is leveraging Viz.ai’s Viz Connect solution to simplify neuro and EP collaboration in this HRX 2024 interview.
- Predicting Coronary Events With Plaque Analysis: How can measuring non-calcified plaque burden change how we detect heart disease? Tune-in to Cleerly’s on-demand webinar featuring Sarah Bär, MD, PhD to discover how Cleerly’s AI-powered coronary CTA plaque analysis is reshaping CAD risk prediction, beyond standard tests.
- Making the Leap to Outsource Post-Processing: Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
- Discover Innovation in Intervention: Explore how the AGENT™ Drug-Coated Balloon from Boston Scientific is advancing U.S.-based treatment options for patients with coronary artery disease. Rx Only. (Sponsored by Boston Scientific)
- How to Overcome Cardiovascular Data Challenges: Managing cardiovascular data is a complex and confusing process. Read Optum’s article on the best practices like aggregating multisource data to prevail over common issues related to cardiology data and analytics.
|
|
|
|
|
